Tenax Therapeutics, Inc. (TENX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing novel cardiopulmonary therapies, specifically prioritizing levosimendan for pulmonary hypertension (PH-HFpEF) and imatinib for pulmonary arterial hypertension (PAH). This report covers the quarterly period ended September 30, 2025. The Company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(15.8) million | $(4.0) million | $(37.1) million | $(11.3) million |
| Operating Expenses | $16.8 million | $4.6 million | $39.9 million | $12.2 million |
| Research & Development | $10.3 million | $3.1 million | $22.1 million | $8.1 million |
| General & Administrative | $6.5 million | $1.5 million | $17.8 million | $4.1 million |
| Cash and Equivalents (End of Period) | $99.4 million (as of Sept 30, 2025) | |||
| Working Capital | ||||
| Net Cash Used in Operating Activities (YTD) | $(22.4) million | $(11.3) million | ||
| Net Cash Provided by Financing (YTD) | ||||
| Net Cash Provided by Financing (YTD) | $26.9 million | $99.8 million |
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased 264% quarter-over-quarter and 227% year-over-year. This is primarily driven by the expansion of the Phase 3 LEVEL clinical trial and the initiation of the LEVEL-2 global trial.
- R&D Costs: R&D expenses rose 232% in Q3 and 173% YTD, reflecting increased clinical site costs, CRO fees, and regulatory consulting.
- Stock-Based Compensation: A significant non-cash driver of expenses. Stock-based compensation in G&A increased by $4.5 million in Q3 (from $12k in Q3 2024) and $11.4 million YTD, largely due to option grants in late 2024 and early 2025.
- Financing Activity: The Company raised $23.2 million in net proceeds from a private placement in March 2025. In contrast, the prior year YTD saw $98.5 million in proceeds from August and February 2024 offerings.
- Interest Income: Increased 53% in Q3 and 227% YTD due to higher cash balances from recent financings and elevated interest rates.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash resources ($99.4 million) are sufficient to fund operations through 2027.
- Clinical Milestones: Patient enrollment in the Phase 3 LEVEL study is ongoing, with an expectation to enroll 230 patients in the first half of 2026. The Company plans to commence the LEVEL-2 global trial in 2025.
- Strategic Focus: The Company has deprioritized the Phase 3 trial of imatinib to focus resources on levosimendan.
- Risks: Continued reliance on equity financing may lead to significant shareholder dilution. The Company has an accumulated deficit of $351.9 million and expects to incur losses for the foreseeable future. Success depends on clinical trial outcomes and regulatory approvals.
- Contingencies: The Company has a license agreement with Orion Corporation involving potential milestone payments (up to $45 million in commercialization milestones and $10 million upon FDA approval), though no liability has been recorded as milestones have not been met.
Investor Verification Checklist
- Cash Runway: Verify the $99.4 million cash balance against the projected burn rate to confirm the "through 2027" liquidity assertion.
- Stock-Based Compensation: Review the $14.4 million YTD stock-based compensation expense and the $18.4 million of unrecognized future costs to assess future dilution and expense impact.
- Warrant Activity: Note the significant number of outstanding warrants (approx. 19 million) and pre-funded warrants (approx. 34 million) which represent substantial potential dilution.
- Clinical Progress: Monitor the enrollment rates for the LEVEL trial and the timeline for the LEVEL-2 trial commencement.
- License Obligations: Track progress toward the $10 million FDA approval milestone and $45 million commercial milestones owed to Orion Corporation.